Literature DB >> 2663143

Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma.

E J Pawlak-Byczkowska1, H J Hansen, A S Dion, D M Goldenberg.   

Abstract

Using the Raji cell line as the immunogen source, we established stable murine hybridomas that secrete B-lymphocyte-specific monoclonal antibodies (MAbs). Two clones, designated EPB-1 and EPB-2, were selected for further study. Both EPB-1 and EPB-2 were typed by reaction with subclass-specific rabbit anti-mouse antibodies and were found to be IgG1 and IgG2a, with kappa-light chains, respectively. In radioimmunobinding and flow cytometric assays, EPB-1 and EPB-2 did not react with T-cell lines, nor with normal diploid cells. EPB-2, in contrast to EPB-1, did not react by flow cytometry with normal peripheral or bone marrow leukocytes. In normal lymphoid tissues, both antibodies were positive with germinal center and mantle zone B-lymphocytes. Additionally, EPB-1 also labeled interdigitating histiocytes in the T-cell zones. Both MAbs discriminated very well between lymphoid and nonlymphoid tissues; neither MAb cross-reacted with tested normal and solid tumor tissue specimens, or with cell lines of non-B-cell origin. Immunohistology also revealed that both MAbs stained malignant lymphoma tissue sections and cloned B-cell lymphomas, both in tissue culture and as human xenografts in nude mice. Due to the radiosensitivity of human lymphomas and the relative specificity of these two new MAbs, they appear to be potential radioimmunotherapeutic agents for human lymphoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663143

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

Authors:  R Stein; E Belisle; H J Hansen; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

2.  Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas.

Authors:  H J Hansen; G L Ong; H Diril; A Valdez; P A Roche; G L Griffiths; D M Goldenberg; M J Mattes
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

3.  Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines.

Authors:  G L Ong; D M Goldenberg; H J Hansen; M J Mattes
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

4.  Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

Authors:  David V Gold; Rhona Stein; Jack Burton; David M Goldenberg
Journal:  Int J Clin Exp Pathol       Date:  2010-11-23

5.  Lymphoma imaging with a new technetium-99m labelled antibody, LL2.

Authors:  S Murthy; R M Sharkey; D M Goldenberg; R E Lee; C M Pinsky; H J Hansen; K Burger; L C Swayne
Journal:  Eur J Nucl Med       Date:  1992

Review 6.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 7.  [Novel B-cell directed strategies for the treatment of rheumatic diseases].

Authors:  I H Tarner
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

8.  Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

Authors:  Rhona Stein; Mitchell R Smith; Susan Chen; Maria Zalath; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

9.  Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.

Authors:  Zhengxing Qu; David M Goldenberg; Thomas M Cardillo; Victoria Shi; Hans J Hansen; Chien-Hsing Chang
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

10.  IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival.

Authors:  Inbal Binsky; Michal Haran; Diana Starlets; Yael Gore; Frida Lantner; Nurit Harpaz; Lin Leng; David M Goldenberg; Lev Shvidel; Alain Berrebi; Richard Bucala; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.